Sign In
Buy LOBEF
$0.0889
+0.0166 (+22.96%)
At Close: Jun 03, 2026
Lobe Sciences Announces Proposed Shares for Debt Transaction
10:00pm, Monday, 01'st Jun 2026
VANCOUVER, BC / ACCESS Newswire / June 1, 2026 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE.F), a clinical-stage biopharmaceutical company that advances high-potential drug candidates f
Lobe Sciences Ltd. Announces Participation in the D.
08:00pm, Wednesday, 06'th May 2026
VANCOUVER, BC / ACCESS Newswire / May 6, 2026 / Lobe Sciences Ltd. ("Lobe", or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE.F), a clinical-stage biopharmaceutical company that advances high-p
Lobe Sciences Reports Second Quarter 2026 Results and Highlights Continued Operational Progress
06:00am, Wednesday, 06'th May 2026
VANCOUVER, BC / ACCESS Newswire / May 6, 2026 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE.F), a clinical-stage biopharmaceutical company that advances high-potential drug candidates th
Lobe Sciences Ltd. Comments on White House Executive Order Supporting Drug Development for Neurological and Mental Health Disorders
08:00am, Thursday, 23'rd Apr 2026
VANCOUVER, BC / ACCESS Newswire / April 23, 2026 / Lobe Sciences Ltd. ("Lobe Sciences" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F), a clinical-stage biopharmaceutical company focused on adva
Lobe Sciences Ltd. Engages Massive Intelligence Pty Ltd for Investor Relations and Corporate Communications Services
06:00am, Tuesday, 21'st Apr 2026
VANCOUVER, BC / ACCESS Newswire / April 21, 2026 / Lobe Sciences Ltd. ("Lobe Sciences" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE), a clinical stage biopharmaceutical company focused on develo
Lobe Sciences Ltd. Announces Closing of Non-Brokered Private Placement and Provides Corporate Update
06:00am, Monday, 20'th Apr 2026
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. VANCOUVER, BC / ACCESS Newswire / April 20, 2026 / Lobe Sciences Ltd.
Lobe Sciences Ltd. Announces Non-Brokered Private Placement
08:00pm, Friday, 10'th Apr 2026
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. VANCOUVER, BC / ACCESS Newswire / April 10, 2026 / Lobe Sciences Ltd.
Lobe Sciences Ltd. Reports Improved Financial Position and Strategic Update
08:20am, Wednesday, 25'th Mar 2026
Liabilities reduced 81%, from $2.35M to $0.44M Cash increased more than 24x, from $0.24M to $5.99M Net working capital improved by $6.1M, from ($2.01M) to $4.05M Outstanding warrants reduced by ~70%,
Lobe Sciences Announces Appointment of Mr. Mirza Rahimani, CPA, CA as Chief Financial Officer
12:00am, Monday, 09'th Mar 2026
VANCOUVER, BC / ACCESS Newswire / March 9, 2026 / Lobe Sciences Ltd. (Lobe) (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE) is a Canadian public biopharmaceutical company incorporated in British Columbia, wit
Lobe Sciences Ltd. Announces Presence in Miami During the Jefferies and Leerink Healthcare Conferences
07:40am, Thursday, 05'th Mar 2026
VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / March 5, 2026 / Lobe Sciences Ltd. (Lobe) (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE) is a Canadian public biopharmaceutical company incorporated in British
Lobe Sciences Reports First Quarter 2026 Results and Highlights
07:00am, Tuesday, 03'rd Feb 2026
VANCOUVER, BC / ACCESS Newswire / February 3, 2026 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE.F) ("Lobe" or the "Company"), a biopharmaceutical company advancing programs in diseases
Lobe Sciences Advances Governance and Capital Markets Expertise with Appointment of Mr. Nick Karakochuk to the Board of Directors
07:00am, Tuesday, 13'th Jan 2026
VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / January 13, 2026 / Lobe Sciences Ltd. ("Lobe Sciences" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F), a clinical-stage biopharmaceutical company
Lobe Sciences Reports FY2025 with a Stronger Balance Sheet and Sharpened Strategy
08:55am, Thursday, 08'th Jan 2026
Balance Sheet and Sharpened Strategy VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / January 8, 2026 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE.F) ("Lobe" or the "Company"), a biophar
Lobe Sciences Reports Fiscal 2025 Results and Highlights Strategic Transformation Following Leadership Transition
06:00am, Tuesday, 06'th Jan 2026
VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / January 6, 2026 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F) ("Lobe" or the "Company"), a biopharmaceutical company advancing programs in di
Lobe Sciences Completes Debt Settlement to Improve Balance Sheet
11:50pm, Thursday, 23'rd Oct 2025
VANCOUVER, BC / ACCESS Newswire / October 23, 2025 / Lobe Sciences Ltd. ("Lobe" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F), operates as a pharmaceutical platform that develops novel therapi
